Related Experiment Video
Updated: Aug 18, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Risk of antibiotics associated with Clostridioides difficile infection: Antibiotic stewardship in action
Andrew T Dysangco1,2,3,4, Tamra M Pierce5, Dawn M Bravata1,2,3,4,6,7
1Department of Veterans' Affairs (VA) Health Services Research and Development (HSR&D) Precision Monitoring to Transform Care (PRISM) Quality Enhancement Research Initiative (QUERI), Indianapolis, Indiana.
Abstract:
We examined risk associated with antibiotics used for Clostridioides difficile infection (CDI) at a single site from 2018 through 2020. Overall, 78 patients had nonrecurrent infections. Among inpatient antibiotics, intravenous meropenem had the highest CDI rate (3.56 per 1,000 days of therapy; n = 2 cases). Among outpatient antibiotics, metronidazole had the highest rate (0.071 per 1,000 pills dispensed; n = 3 cases).
Insights
This study investigated antibiotic risks for Clostridioides difficile infection (CDI). Intravenous meropenem and oral metronidazole showed the highest associated CDI rates in inpatient and outpatient settings, respectively.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Clostridioides difficile infection (CDI) is a significant healthcare-associated infection.
- Antibiotic use is a primary risk factor for CDI development and recurrence.
- Understanding specific antibiotic risks is crucial for infection prevention strategies.
Purpose of the Study:
- To assess the risk of CDI associated with specific inpatient and outpatient antibiotic agents.
- To identify antibiotics with the highest CDI incidence rates at a single institution.
Main Methods:
- Retrospective analysis of CDI cases and antibiotic utilization data from 2018-2020.
- Calculation of CDI rates per 1,000 days of therapy for inpatient antibiotics.
- Calculation of CDI rates per 1,000 pills dispensed for outpatient antibiotics.
Main Results:
- A total of 78 patients with nonrecurrent CDI were analyzed.
- Intravenous meropenem exhibited the highest inpatient CDI rate (3.56 per 1,000 days of therapy).
- Metronidazole demonstrated the highest outpatient CDI rate (0.071 per 1,000 pills dispensed).
Conclusions:
- Certain antibiotics, including intravenous meropenem and oral metronidazole, are associated with higher CDI risks.
- These findings can inform antibiotic stewardship and CDI prevention efforts.
- Further research is warranted to explore causative mechanisms and refine treatment guidelines.
Related Concept Videos
Antibiotic Selection
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Development of Antibiotic Resistance
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

